<DOC>
	<DOC>NCT01822080</DOC>
	<brief_summary>This study is aimed to evaluate efficacy and safety of dienogest 2 mg oral tablets in the treatment of endometriosis. There will be 2 study phases: a double-blind, randomized, placebo-controlled, parallel-group phase over 24 weeks, and an open-label extension phase with 2 mg DNG daily p.o. over 28 weeks for all subjects who completed the double-blind phase, irrespective of their treatment assignment in the first study phase.</brief_summary>
	<brief_title>Phase 3 Study of Dienogest for the Treatment of Endometriosis in Chinese Patients</brief_title>
	<detailed_description />
	<mesh_term>Endometriosis</mesh_term>
	<mesh_term>Dienogest</mesh_term>
	<mesh_term>Nandrolone</mesh_term>
	<criteria>Women between 18 and 45 years of age, inclusive Women with endometriosis confirmed by laparoscopy or laparotomy within ten years but no later than 2 weeks before the Screening Visit A score of at least 30 on a 100 mm visual analog scale (VAS) for endometriosisassociated pelvic pain at Screening Visit and Baseline Visit Good general health (except for findings related to endometriosis, with or without infertility), as evidenced by medical history and complete physical and gynecological examination Willingness to use a barrier method of contraception is required Pregnancy or lactation (less than three months since delivery, abortion, or lactation before start of treatment) Wish for pregnancy within intended treatment period Before menarche or after menopause Amenorrhea (more than three consecutive months in the six months before screening) Undiagnosed abnormal genital bleeding Previous/use of hormonal agents Any disease or condition that may worsen under hormonal treatment Signs and/or symptoms of therapyresistant endometriosis despite more than one prior attempt at drug treatment or surgical therapy Need for primary surgical treatment of endometriosis Regular use of pain medication due to other underlying diseases Contraindication for the supportive analgesic medication (ibuprofen)</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Endometriosis</keyword>
	<keyword>Efficacy</keyword>
	<keyword>Safety</keyword>
	<keyword>Dienogest</keyword>
</DOC>